Modern - Blog Science Connections

More documents

Recommendations

Info

Methotrexate -, intermediate dose of 99 -, resistant dihydrofolate reductase 167 -, treatment with 47 Methylation of DNA 201 -, ofviralDNA 199 Methylnitrosourea, induction of leukemia in culture 273 Microinjection, intracellular 143 Moloney murine sarcoma virus (MSV) , doned fragments 462 Monodonal antibodies 179,294,296,309,360,548 --, against hemopoietic precursor cells 296, 310 --, OKT297, 311 Mononucleosisinfectiousa,EBVin4, 179, 191 - -, killer cells in 347 Murine leukemia virus, fibroblast transformation 479 ---, surface receptors for 360,363 Mutation in malignancy 163 Mycosis fungoides 502, 515 Myeloid differention, expression of lysozyme gene in 177 - -, dysplasia 34 - - -, chromosome determinants in 8 ---, TDTin 76 Myeloperoxidase 256 - in bone marrow cultures 277,291 - in plasma dot cultures 256 Myelopoiesis, genetic and oncogenic influences 237 -, inhibition of 238 -, regulation of 241 Nasopharyngeal carcinoma 179 --, EBVin 192 --, karyotypesof 195 Natural killing 345 --, cells351 Nephroblastomas, virus induced 452 Network concept 343 Nude mice, Hodgkin celllines in 232 OKT series of monodonal297, 311 Oncgen 387, see also gene -, designs 390 Oncogenetic influences on myelopoiesis 237 Oncorna virus in human leukemia 502, 527 Osteosarcoma, virus induced 452 Papovavirus 3 -, B-Iymphotropic 204 Philadelphia chromosome in leukemia 27, 164 Phosphoproteins 524 -, gag related 389 Phosphorylation 397 -, gag related 389 - in protein synthesis 148,414 -, ofinitialfactor 147 -, phosphoproteins 524 Plasma dot cultures 255 pp60 src 397, 402, 405, 411 Precursor polypeptides 524 Prednisolone, treatment with 47 Preleukemia, histopathology of 34 -, induction in bone marrow culture 274 -, phi-chromosom in 37 Prognostic factors in leukemia 78,82,90,112,118, 121 Promoter, insertion model for leukemogenesis 444 -, tumor 201 Prostagiandines, effect of leukemia cell differentiati on 270 -, inhibition of CFU -C proliferation by 238 -, production of 239 Protein kinase 398, 402, 405, 414 - -, of the HS-HL system 147 - - in leukemic cells 225 Protein synthesis, control of 414 -, inhibition by HS, HL-heme 148 --, byinterferon-ds RNA 148 -, initiation factor in 146,414 Provirus, moloney sarcoma (-mos) 460 Radiation, induced murine leukemia 538 Raji-cellline 182 Recombinants of viruses 435,457 Read-Sternberg cell12, 229 --, cytochemistry of 13, 232 Relaps in childhoodleukemia 94, 101, 114, 121 -, CNS 81,101,119,121 - in T -cell leukemia 122 -, leukemic 94 -, testicular81, 114, 119, 121 -, therapyof95, 112 Remission in AML 40, 47, 140 ---, after bone marrow transplantation 140 -, cause of death in 109 -, CFU-C in 252,256 - in childhood leukemia 81, 90, 96,103,111,117, 122 - in T -cell leukemia 122 Restriction analysis 430 --,ofSFFV-DNA475 --,oftumorDNA441,446,496 Retrovirus 383,547 -,endogenes537 -, genes in thymic nurse cells 374 - in human teratocarcinoma cell lines 541 Reverse transcriptase in thymic epithelial cells 374 -- in human T-cell leukemia virus 509 - - in thymic epithelial cells 374 Risk index in leukemia 82, 89,101,118 RNA, heterogeneous 517 555
RNA -, of tumor virus 439 Rous sarcoma virus 383, 402 Sarcoma virus 384, see also virus Sezary syndrome 502 Simian sarcoma virus 409,520,524 ---, non producercells 520, 524 ---, p30 positiv immunreaction in human leukemia 528,530 ---, protein411 ---, transformation specific glycoprotein 521 6-Mercaptopurine see chemotherapy 6-Thioguanine see also chemotherapy -, treatment in AML 54 Src-gene 385,402 Suppressor cell in Hodgkin's disease 19 Surface markers in Hodgkin celllines 231 - - in leukemia lymphoma celllines 324, 456 -- in U-937 cells 218 Susceptibility theory of Hodgkin's disease 15 Target cells for AEV 419 --, fortransformation455, 468 - -, hemopoietic 417 T-cell -, alloreactive 320 -, antigen 297,311 -, anti-human globulin against 129 -, clones see hybridomas -, culture 301, 507 -, cytotoxic 321,343,346,377 -, differention 372 -, growth factor 70,294, 320, 343, 503 -, helper 294,320 -, hybridomas 294,320,360 - in Hodgkin disease 19 -, leukemia5, 70,90,122,505,515 -,line505 -, toHLA-antigenes311 -, triosomyin 15 Teratocarcinoma 8 -, retrovirus in human 541 Terminal deocynucleotidyl transterase in leukemia 68,296 - and response to therapy 71 - in lymphomas 69 - in normaltissues 296 - in T -cell differentiation 311, 503 Thymic, lymphomas 360 -, nurse cells 372 - -, expression of retroviral determinants in 374 Thymidin, high dose therapy in leukemia 75 Transfection, with subgenomic DNA fragments 462 Transformation -, chromosomes in see chromosomes -, of bone marrow cells 168 -, of fibroblasts 479 -, ofhumanHCI-8cells 171 -, specific antigens 485,521 -, subgenomic fragments induced 461, 476 -, targetcellsfor455,467 -, virus induced 384, 417 Transforming gene 168, 171, 383,441 - -, activity of cJoned MSV fragments 462 --, products 397 --, proteins 391 Translation of viral RNA 389 ---, limited by interferron 148 ----, byhyperthermia 148 Translocation 151 -, forph1-chromosomes 28 - inCMC164 - in myeloblastic leukemia 30 Transplantation of bone marrow 132, 136, 140 - - - -, prevention of GvHD by T -cell anti sera 132 - in leukemia 132, 136, 140 Transposable genetic elements 152 Treatment see also chemotherapy and leukemia -, ofALL 79,88,91,100,108,116 -, of AML (ANLL) 2, 22, 53 -, ofT-cellleukemia 122 -, with drug loaded erythrocyts ghosts 143 -, withimmunotherapy 139, 343 -, with transplantation 132, 136 Trisomy 7 in lymphoma celllines 180 -, 15 in T -cellleukemogenesis 6 Tumorcell --, associated transplantation antigens 377 --, cJonal origin 447 --, evolution 9 --, growth, stimulated by anti-idiotypic lymphocytes368 --, immunoadaptionof378 --, metastasis 368, 377 --, specificDNA446 Tupaia, bone marrow cultures 281 12-Tetra-decanoyl-phorbol-13-acetate (TPA), differentiation of human leukemic cells by 315 U 3 -region in growth 433 - in leukemogenesis 435 U-937 cellline 215 V APA 10 treatment of AML with 45 Vincristine see also chemotherapy -, treatment with in AML 39, 47, 54 Viral see also virus -, antigens 184, 230 -- inhumanleukemia 527,530 -- in humoral immune response 485, 492 -,DNA198 --, restriction analysis of 441,446,496 -, expression in differentiating lymphocytes 366 556
Page 1 and 2:
Haematology and Blood Transfusion 2
Page 3 and 4:
Dr. Rolf Neth, Universitäts-Kinder
Page 5 and 6:
Participants of the Meeting Aaronso
Page 7 and 8:
Kurth, R, Friedrich-Miescher-Labora
Page 9 and 10:
Wilsede Scholarship Holders (Grante
Page 11 and 12:
Preface Gut ist eine Lehrart, wo ma
Page 13 and 14:
Personal and scientific discussion
Page 15 and 16:
Acknowledgement We should like to t
Page 17 and 18:
Wilsede, June 21 1978 Memorial Trib
Page 19 and 20:
limiting benign lymphoproliferative
Page 21 and 22:
this most unlikely, however (for re
Page 23 and 24:
longer subject to the same control
Page 25 and 26:
Bregula U, Wiener F, Harris H (1971
Page 27 and 28:
fresh lymph node biopsies from ten
Page 29 and 30:
Fig. 3. Binucleate mitosis in an ob
Page 31 and 32:
y Fig. 4. Schematic diagram of post
Page 33 and 34:
than that among patients with Stage
Page 35 and 36:
Tests of binding affinity, agglutin
Page 37 and 38:
N Engl J Med 297: 963-968 - Green I
Page 39 and 40:
Clinical Aspects
Page 41 and 42:
"ring chromosome". "Mar" is marker,
Page 43 and 44:
191 chromosomally abnormal patients
Page 45 and 46:
tumors of both African and non-Afri
Page 47 and 48:
Haematology and Blood Transfusion V
Page 49 and 50:
Retrospective group 26/93 evolved l
Page 51 and 52:
Page 53 and 54:
Treatment
Page 55 and 56:
advantage in terms of duration of f
Page 57 and 58:
leukaemia. An analysis of 168 patie
Page 59 and 60:
11. Treatment Program Chemotherapy
Page 61 and 62:
efractory congestive heart failure
Page 63 and 64:
period (Sequence II) was gene rally
Page 65 and 66:
children with a multiple drug proto
Page 67 and 68:
DAYS 1 5 10 15 20 25 30 35 , I I I
Page 69 and 70:
Biologically Drug Outcome fit" sens
Page 71 and 72:
may counterbalance the potential be
Page 73 and 74:
Ht (0--0) 50 40 30 20 10 0 Platelet
Page 75 and 76:
10 7 ,-----------------------------
Page 77 and 78:
11. Haematological and Biochemical
Page 79 and 80:
0\ 0\ INTERFERON ... 10 3 rl E "'
Page 81 and 82:
Page 83 and 84:
("pre-B" phenotype) has been descri
Page 85 and 86:
human bone marrow cells exhibit the
Page 87 and 88:
10 9.,0 MBKCC .. .,4 B prot:oool 1'
Page 89 and 90:
demann W, Büehner T, Arlin Z, Gee
Page 91 and 92:
-...l 00 a-tLDRENS CAt«:ER S TU>Y
Page 93 and 94:
prognostic characteristics under in
Page 95 and 96:
significantly higher in HR} (14.5%,
Page 97 and 98:
normal or elevated immunoglobulin l
Page 99 and 100:
References Andreeff M, Darzynkiewic
Page 101 and 102:
R GROUP 1 ( 1970 - 1971 ) 17 PTS. R
Page 103 and 104:
Table 3. Influence of initial featu
Page 105 and 106:
LIJ (f) a.. < -1 LIJ Q: u. 0 >- I-
Page 107 and 108:
Page 109 and 110:
me nt indicated that additional the
Page 111 and 112:
42:2123-2134 - Chessells JM, Cornbl
Page 113 and 114:
Baum et al. 1979). This study was b
Page 115 and 116:
1. 0 '--'1--" 0.9 e: o .- VI VI E C
Page 117 and 118:
e: o e: 1. 0 ,.--...-- 1'"'\ ......
Page 119 and 120:
In conclusion, we can state that th
Page 121 and 122:
Haematology and Blood Transfnsion V
Page 123 and 124:
INDUCTION VCR + PRED + ASNASE (wk 3
Page 125 and 126:
SCHED.INT 1 MTX • ! Adria MTX •
Page 127 and 128:
~ looh---------ooooc>----o---c>----
Page 129 and 130:
Consoll- Irra .tlon t) .tlon Indu
Page 131 and 132:
Highrisk Standard risk Table 1. Cli
Page 133 and 134:
Cumulo/ive comp/el9 remission 1.0 .
Page 135 and 136:
10° 8 = 6 ö 4 Non T Cell .~ :ö
Page 137 and 138:
Page 139 and 140:
% SURVIVAL 100 ~ ~II 0 80 60 40 - -
Page 141 and 142:
a) Percentage of donor cell mitoses
Page 143 and 144:
Table 5. Results of bone marrow tra
Page 145 and 146:
...... w N Table 7. Clinical result
Page 147 and 148:
agent had to be added and that in t
Page 149 and 150:
Page 151 and 152:
C. Chronic Myelogenous Leukemia The
Page 153 and 154:
Patients with a suitable donor rece
Page 155 and 156:
No. Recurrent Leukaemia Other death
Page 157 and 158:
followed by dialysis against isoton
Page 159 and 160:
Page 161 and 162:
HS, HL- Heme >_ 40 0 HS I ;:. =====
Page 163 and 164:
Page 165 and 166:
knowing at present. These genes may
Page 167 and 168:
esistance to antifolates. In Vitro
Page 169 and 170:
a DNA probe specific for the gene t
Page 171 and 172:
translocation between chromosomes 9
Page 173 and 174:
Table 1. Subdivision of 1827 Myelo-
Page 175 and 176:
NORMAL CELL ®
Page 177 and 178:
some change of the primary type, in
Page 179 and 180:
Page 181 and 182:
F. Transformation of Mouse Bone Mar
Page 183 and 184:
Page 185 and 186:
were carried out with 3H-MTX in the
Page 187 and 188:
Page 189 and 190:
the lysozyme cDNA prepared from ovi
Page 191 and 192:
Page 193 and 194:
et al. 1976). The BJAB cellline in
Page 195 and 196:
dalton bands corresponding to light
Page 197 and 198:
1979). The EBV-carrying cell lines
Page 199 and 200:
producer lines (DAUDI and P3HR-1),
Page 201 and 202:
G, Giovanella B, Westman A, Stehlin
Page 203 and 204:
Page 205 and 206:
Dc;bt CT + i J.I9 Raji; 1. i .. 100
Page 207 and 208:
c. Discussion During infectious mon
Page 209 and 210:
Page 211 and 212:
C. Nonepisomal Viral DNA We have us
Page 213 and 214:
A 260 3.0 A B 1670 70 N2 2.0 c: E .
Page 215 and 216:
vivo. Nature 260:302-306 - Kirk JTO
Page 217 and 218:
Fig. 1. a Polyacrylamide gelelectro
Page 219 and 220:
Page 221 and 222:
1979). The lymphocyte subpopulation
Page 223 and 224:
lysin 0 antigens are found, and mix
Page 225 and 226:
Pope JH (1978) Long-term T cell-med
Page 227 and 228:
Page 229 and 230:
Charaeteristie Morphologie maturati
Page 231 and 232:
after TPA-induction (Table 3). The
Page 233 and 234:
PA (1978) Reactivity of a rabbit an
Page 235 and 236:
Blood Monocyte. B lood Monocytes 1-
Page 237 and 238:
Page 239 and 240:
and nonhistone proteins can serve a
Page 241 and 242:
Page 243 and 244:
The findings of the evaluation of s
Page 245 and 246:
Fig. 3. Tumor grawth of L 428 cells
Page 247 and 248:
Cell biological and Immunological A
Page 249 and 250:
consideration. Sanel (1973) obtaine
Page 251 and 252:
endotoxin serum, were used. A parti
Page 253 and 254:
monocytic leukemia cell line in cul
Page 255 and 256:
B. Isolation, Characterization and
Page 257 and 258:
Page 259 and 260:
don al hemopathies generally displa
Page 261 and 262:
nitors. Blood Cells 6:595-607 - Min
Page 263 and 264:
\I) ....I ....I IU Jl 200 r 100 90
Page 265 and 266:
their haemopoietic cells' ability t
Page 267 and 268:
normal normal ALL ALL ALL persons p
Page 269 and 270:
64.5 { V)
Page 271 and 272:
References Biermann E, Neth R, Gros
Page 273 and 274:
ehambers, the growth pattern observ
Page 275 and 276:
References Anderssen LC, 10kinen M,
Page 277 and 278:
REH CELL UNE TO CALLb~Ö ~q~ V.M. c
Page 279 and 280:
Page 281 and 282:
the macrophage series in which the
Page 283 and 284:
Page 285 and 286:
Table 1. Production of factor depen
Page 287 and 288:
Page 289 and 290:
Table 1. Characteristics of the adh
Page 291 and 292:
Fig. 3. A human marrow culture at 6
Page 293 and 294:
300 250 • HYPERPROLIFERATIVE PATT
Page 295 and 296:
Fig. 9. Nonadherent population from
Page 297 and 298:
The cobblestone areas were often no
Page 299 and 300:
L (1976) Induction of colony format
Page 301 and 302:
B. Materials and Methods J. Tissue
Page 303 and 304:
Fig. 2. Ultrastructural appearance
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Table 1. Monoclonal antibody reacti
Page 311 and 312:
al. 1979; Janossy et al. 1979) is e
Page 313 and 314:
to which this is an exact replica o
Page 315 and 316:
inger JL (1976) Distribution of la-
Page 317 and 318:
I region antigens were found to be
Page 319 and 320:
have been reported to be present on
Page 321 and 322:
V. FunctionalAssays Assays for PHA
Page 323 and 324:
Functional studies of UCHT1 separat
Page 325 and 326:
Page 327 and 328:
40 ,...... (5 L.. C o u 30 .9 ~ .~
Page 329 and 330:
with immunohistochemieal methods (L
Page 331 and 332:
Page 333 and 334:
can be dissected by cloning. Utiliz
Page 335 and 336:
Table 1. Origin and marker profile
Page 337 and 338:
Page 339 and 340:
complete identity of gp 100 from no
Page 341 and 342:
Table 1. Reaction of single anti se
Page 343 and 344:
Page 345 and 346:
media. Following 24-h incubation, c
Page 347 and 348:
nonleukemic eells (Greaves 1979). L
Page 349 and 350:
Page 351 and 352:
Fig. 2. Cytocentrifuged smears of b
Page 353 and 354:
Modification of amino-groups of hum
Page 355 and 356:
disturb this balance in the directi
Page 357 and 358:
The majority of human blood lymphoc
Page 359 and 360:
of the EBV infected B cells. Howeve
Page 361 and 362:
and immunoglobulins. J Immunol 120:
Page 363 and 364:
" K 10 • j ~ ALL RNlL AL wtfh les
Page 365 and 366:
tion akuter Leukämiezellen in "spo
Page 367 and 368:
D. Results and Discussion J. Acute
Page 369 and 370:
selectively responsive to different
Page 371 and 372:
Page 373 and 374:
l1J ~ 100 ~ Q. ::) l1J Z 0 ~ z >- .
Page 375 and 376:
Table 2. Growth inhibition of S49 e
Page 377 and 378:
Reverse Infectious ASC/2X1Q6 transc
Page 379 and 380:
Page 381 and 382:
munized animals to 1316 tumor cells
Page 383 and 384:
Page 385 and 386:
Fig. 3. Expression of retroviral gp
Page 387 and 388:
pg70. J Exp Med 143: 151-166 - McGr
Page 389 and 390:
Table 1. Expression of tumor antige
Page 391 and 392:
Virological and Molecularbiological
Page 393 and 394:
Table 1. Oncogenic properties of re
Page 395 and 396:
also Fig. 1). It followed that the
Page 397 and 398:
whether this sequence is related to
Page 399 and 400:
zed in infected cells argue that th
Page 401 and 402:
a specific viral transforming prote
Page 403 and 404:
detect viral RNA as the only charac
Page 405 and 406:
Eisen H (1980) Myeloproliferate vir
Page 407 and 408:
p,60- -34K - 1 2 3 4 Fig. 1. In vit
Page 409 and 410:
.. p - • a'T ... I .t'l Fig. 4. D
Page 411 and 412:
Page 413 and 414:
Fig. 2. Photomicrographs of NY68 in
Page 415 and 416:
DEAE (o(lJmn 'liI GI -2 2 o e s 1
Page 417 and 418:
vity was deterrnined. For endogenou
Page 419 and 420:
pr 180 - - - P 12/15 - A B c D E F
Page 421 and 422:
85,- 66- -27 - -66 40- 27- -1'9 19-
Page 423 and 424:
Page 425 and 426:
= 0.5 o E Q. o ILI 0.4 (J) « ILI .
Page 427 and 428:
Table 1. Oncogenic potential of avi
Page 429 and 430:
100 III GI c: o "8 80 > w
Page 431 and 432:
Expt. No. Infecting virus Proportio
Page 433 and 434:
Haematology and Blood 'fransfusion
Page 435 and 436:
sequences, provided its gag portion
Page 437 and 438:
77:3009-3013 - Hu SSF, Moscoviei C,
Page 439 and 440:
RI 2.2 md and Hind III 2.6 md leuke
Page 441 and 442:
Page 443 and 444:
RELATIONSHIP OF ENDOGENOUS AND EXOG
Page 445 and 446:
E ........ E Cl. U E :::l .... Q) (
Page 447 and 448:
References Astrin S (1978) Endogeno
Page 449 and 450:
the same animal were examined (e.g.
Page 451 and 452:
I) 'IQ a \0 - CL -- Fig. 2. Restrie
Page 453 and 454:
~ ..................... ~ Cell 3' 5
Page 455 and 456:
a :Sa,C! + . ~ 111 i' ( " '~ .J. b
Page 457 and 458:
Table 1 Sampie Tissue TS fragment"
Page 459 and 460:
a b Sac I / rep ._-_.-_ K J nl rep
Page 461 and 462:
Haematology and Blood 'fiansfusion
Page 463 and 464:
Osteopetrosis and osteosarcomas occ
Page 465 and 466:
Lymphoma cellline Table 1. T and B
Page 467 and 468:
Table 2. In vivo growth and oneogen
Page 469 and 470:
Page 471 and 472:
Table 1. Transforming aetivity of c
Page 473 and 474:
Table 3. Transformation aetivity of
Page 475 and 476:
- Shoemaker C, Goff S, Gilboa E, Pa
Page 477 and 478:
indieate a shifting of target eell
Page 479 and 480:
Table 2. Expression of Jl and Sourc
Page 481 and 482:
Page 483 and 484:
~ i ,..1---------,,':::::::::::::::
Page 485 and 486:
fragment of pBR322 DNA, a 3.0-kbp S
Page 487 and 488:
Mak TW (1979) Proc Natl Acad Sci US
Page 489 and 490:
Table 1. Transformation of 3T3 cell
Page 491 and 492:
inserts in the genome of rapidly tr
Page 493 and 494:
pulations, it seemed likely that th
Page 495 and 496:
contains antigens which react with
Page 497 and 498:
Page 499 and 500:
le of reacting in sensitive radioim
Page 501 and 502:
Page 503 and 504:
gic approach. In: Hiatt HH, Watson
Page 505 and 506:
12 Eco R [ Fig. 1. Hybridization pa
Page 507 and 508:
Page 509 and 510:
10 - '1~ )( -~ S:! E A U I o 1 2
Page 511 and 512: Haematology and Blood 'fransfusion
Page 513 and 514: cultures. These cells did not conta
Page 515 and 516: indication of malignant T-cells in
Page 517 and 518: Fig. 3. Thin-section electron micro
Page 519 and 520: Table 3. Lack of detectable related
Page 521 and 522: J. HTLV Was Present in the Primary
Page 523 and 524: specific signals into nonspecific s
Page 525 and 526: Table 2. Distribution of HTLV-relat
Page 527 and 528: u 10 ~ 20 ~ :c 30 a 40 o Fig. 1. Ki
Page 529 and 530: Haematology and Blood Transfusion V
Page 531 and 532: SSV TrS-gp labeled effectively with
Page 535 and 536: 60 HFF/SSV cDNA CELL RNAs: 0 HF/SSV
Page 537 and 538: Antisera a Table 1. Immunofluoresce
Page 539 and 540: Haematology and Blood 'ftansfusion
Page 541 and 542: y competition RIA yielded virtually
Page 543 and 544: SiS'V' gp70: ANTIGEN, ANTI BODY, IM
Page 545 and 546: type-C virus p30 antigen in cells f
Page 547 and 548: c. Results The fractionated whole-b
Page 549 and 550: induced antibodies as well as exper
Page 551 and 552: - Fig. la-f. Retravirus particles p
Page 553 and 554: eplication of infecting murine leuk
Page 557 and 558: immunodeficiency, multic10nal lymph
Page 559 and 560: Bovine leukemia --, proteins of 499
Page 561: Human T- cell - -, characterization
Page 565 and 566: Haematology andBlood Transfusion Su
show all

Modern - Blog Science Connections

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?